Design of universal Ebola virus vaccine candidates via immunofocusing

Ebola virus, a member of the Filoviridae family, is highly pathogenic and threat to public health. Two vaccines were developed for prevention of the infection of ebola virus, however they both must be stored in cold room, and they have possibility of causing mild to moderate side effects in vaccinated individuals. Therefore, they have used to a very limited extent. So, we need to design of new prophylactic vaccines that are suitable for widespread use and confer durable and cross-protective immunity. Ebola virus Glycoprotein (GP) mediates viral infection and serves as the primary target of neutralizing antibodies. Hyperglycosylated GP-Fer with two or three additional glycans indicated consistent cross-neutralizing activity against Bundibugyo virus and Sudan virus. GP-based immunogens that have thermostability and elicit cross-protective responses hold promise as effective universal orthoebolavirus vaccine candidates.

(RN)